Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by St. Jude Children's Research Hospital
Sponsor:
Collaborator:
St. Baldrick
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT01701492
First received: October 3, 2012
Last updated: April 7, 2014
Last verified: April 2014
  Purpose

This is an observational study to collect information by use of performance-based measures and survey questionnaires. It does not include interventions aimed at altering patient outcome.

Advances in pediatric hematopoietic stem cell transplantation (SCT) have resulted in improved survival and prompted increased attention to the potential adverse late effects of this procedure. Survivors of SCT are thought to be at risk for neurocognitive deficits as a result of their exposure to a number of potentially neurotoxic agents. Prior studies done by our group and others have demonstrated generally stable cognitive function in the first 5 years following transplant, with little evidence of significant declines. However, there has been almost no research to date on the status of very long-term (> 5 years post-transplant) survivors. In this study, we will evaluate a large sample of long-term survivors of allogeneic SCT using measures of intelligence, academic achievement, and specific cognitive functions such as attention, working memory and processing speed. We will also obtain measures of behavioral functioning and quality of life. We will examine how this group of survivors are functioning relative to normative expectations, and in comparison to community controls without a history of serious illness, matched on age, gender, race/ethnicity, and socioeconomic status. We will also examine the relationship between cognitive function and psychosocial function and quality of life in this population.


Condition Intervention
Stem Cell Transplant During Childhood
Allogeneic Bone Marrow Transplant During Childhood
Other: Questionnaire
Other: Neurocognitive Evaluation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

Resource links provided by NLM:


Further study details as provided by St. Jude Children's Research Hospital:

Primary Outcome Measures:
  • Intelligence and academic achievement [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    To describe global cognitive and academic outcomes in this SCT cohort using measures of intelligence and academic achievement when compared to established normative data on well validated standardized instruments as well as to control participants in the community.

  • Performance in specific neuropsychologic domains. [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    To examine performance in specific neuropsychologic domains, including working memory, processing speed and other executive functions compared to established normative data on well validated standardized instruments as well as to control participants in the community.

  • Psychosocial function [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    To examine psychosocial function among long-term SCT survivors using both self- and parent-report compared to established normative data on well validated standardized instruments as well as to control participants in the community.

  • Quality of life [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    To examine quality of life among long-term SCT survivors using both self- and parent-report compared to established normative data on well validated standardized instruments as well as to control participants in the community.


Estimated Enrollment: 400
Study Start Date: October 2012
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Stem Cell Transplant Survivors
All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
Other: Questionnaire
A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
Other: Neurocognitive Evaluation
A one-time neurocognitive evaluation conducted in the Psychology Clinic
Normal control participants
Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
Other: Questionnaire
A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
Other: Neurocognitive Evaluation
A one-time neurocognitive evaluation conducted in the Psychology Clinic

Detailed Description:

This study will involve a one-time assessment using both performance based measures as well as both self- and parent-report questionnaires. During their yearly visit to St. Jude, eligible patients who agree to participate will undergo a single neurocognitive evaluation. This evaluation will take place in the Psychology Clinic. The administration time for the assessment battery is estimated at 2.5-3.5 hours, with variability depending on the age of the patient and the speed of completion of the tasks. All measures selected for the study have well-established psychometric properties, including acceptable reliability and validity. All measures were standardized on large, representative samples of children and adults and have age-specific norms.

PRIMARY OBJECTIVE:

To examine and describe psychological outcomes in long-term (> 5 years) survivors of allogeneic bone marrow or stem cell transplantation (SCT) in childhood. This will be conducted in a one-time cross-sectional assessment using both performance based measures and survey questionnaires. Comparisons will be made to established normative data on well validated standardized instruments and to control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status.

  • To describe global cognitive and academic outcomes in this SCT cohort using measures of intelligence and academic achievement.
  • To examine performance in specific neuropsychologic domains, including working memory, processing speed and other executive functions.
  • To examine psychosocial function and quality of life among long-term SCT survivors using both self- and parent-report.
  Eligibility

Ages Eligible for Study:   8 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Survivors of SCT who are > 5 years since transplant and are returning for a transplant clinic outpatient follow-up visit will be recruited to participate on study. We will recruit patients beginning at age 8 years, with no upper age limit, although we anticipate that most patients will be between 8 and 25 years at the time of assessment. For patients in the age range 8-21 we will obtain data by both self- and parent-report. However, if patients age 18-21 present to clinic without a parent, they will still be eligible for study, and for these patients, as well as those ≤ 21 years, we will obtain performance based and self-report measures only.

Criteria

Inclusion Criteria:

  • Treated with allogeneic bone marrow or stem cell transplant at St. Jude Children's Research Hospital (SJCRH)
  • ≤ 21 years at time of transplant
  • > 5 years from date of last transplant
  • Currently at least 8 years of age
  • English as primary language

Exclusion Criteria:

  • Transplanted for metabolic storage disorder, osteogenesis imperfecta, osteopetrosis, or dyskeratosis congenita.
  • History of central nervous system (CNS) injury/disease predating or unrelated to reason for SCT
  • Major sensory or motor impairment that would preclude valid cognitive assessment. However, we will not exclude participants with mild cognitive impairments or special educational needs.
  • Prior participation in BMTPE protocol at St. Jude Children's Research Hospital.

Control Group Inclusion Criteria

  • Age at least 8 years
  • No known history of serious illness
  • Demographic match to a St. Jude stem cell transplant patient

Control Group Exclusion Criteria

  • Major sensory or motor impairment that would preclude valid cognitive assessment.
  • History of specific CNS disease/injury (e.g., Down Syndrome, traumatic brain injury). However, we will not exclude participants with mild cognitive impairments or special educational needs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01701492

Contacts
Contact: Sean Phipps, PhD 866-278-5833 info@stjude.org

Locations
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Sean Phipps, PhD    866-278-5833    info@stjude.org   
Principal Investigator: Sean Phipps, PhD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
St. Baldrick
Investigators
Principal Investigator: Sean Phipps, PhD St. Jude Children's Research Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT01701492     History of Changes
Other Study ID Numbers: XPD12-077 BMTPE3
Study First Received: October 3, 2012
Last Updated: April 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by St. Jude Children's Research Hospital:
pediatric
hematopoietic stem cell transplantation
allogeneic bone marrow transplantation

ClinicalTrials.gov processed this record on September 18, 2014